1.
Bioorg Med Chem Lett
; 17(4): 1056-61, 2007 Feb 15.
Artículo
en Inglés
| MEDLINE
| ID: mdl-17157013
RESUMEN
Modulation of PPAR activities represents an attractive approach for the treatment of diabetes with associated cardiovascular complications. The indanylacetic acid structural motif has proven useful in the generation of potent and tunable PPAR ligands. Modification of the substituents on the linker and the heterocycle tail group allowed for the modulation of the selectivity at the different receptor subtypes. Compound 33 was evaluated in vivo, where it displayed the desired reduction of glucose levels and increase in HDL levels in various animal models.
Asunto(s)
Acetatos/síntesis química , Acetatos/farmacología , Hipoglucemiantes/síntesis química , Hipoglucemiantes/farmacología , Indanos/síntesis química , Indanos/farmacología , PPAR alfa/agonistas , PPAR delta/agonistas , PPAR gamma/agonistas , Animales , Área Bajo la Curva , Glucemia/metabolismo , Células Cultivadas , Colesterol/sangre , Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Experimental/genética , Relación Dosis-Respuesta a Droga , Humanos , Hidrólisis , Hipoglucemiantes/farmacocinética , Indicadores y Reactivos , Lipoproteínas HDL/sangre , Ratones , Ratas , Ratas Zucker , Rosiglitazona , Relación Estructura-Actividad , Tiazolidinedionas/uso terapéutico
2.
Bioorg Med Chem Lett
; 14(12): 3155-9, 2004 Jun 21.
Artículo
en Inglés
| MEDLINE
| ID: mdl-15149665
RESUMEN
A series of (5-(2H)-isoxazolonyl) ureas were developed as nanomolar inhibitors of hormone-sensitive lipase, an enzyme of potential importance in the treatment of diabetes.